CA2979544A1 - Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases - Google Patents

Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases

Info

Publication number
CA2979544A1
CA2979544A1 CA2979544A CA2979544A CA2979544A1 CA 2979544 A1 CA2979544 A1 CA 2979544A1 CA 2979544 A CA2979544 A CA 2979544A CA 2979544 A CA2979544 A CA 2979544A CA 2979544 A1 CA2979544 A1 CA 2979544A1
Authority
CA
Canada
Prior art keywords
fumarate
pharmaceutical composition
administering
patient
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2979544A
Other languages
English (en)
French (fr)
Inventor
Ajay Verma
Robert Scannevin
Shyam Karki
Fengmei ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CA2979544A1 publication Critical patent/CA2979544A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2979544A 2015-03-20 2016-03-18 Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases Abandoned CA2979544A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136431P 2015-03-20 2015-03-20
US62/136,431 2015-03-20
PCT/US2016/023021 WO2016153957A2 (en) 2015-03-20 2016-03-18 Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases

Publications (1)

Publication Number Publication Date
CA2979544A1 true CA2979544A1 (en) 2016-09-29

Family

ID=55702079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979544A Abandoned CA2979544A1 (en) 2015-03-20 2016-03-18 Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases

Country Status (15)

Country Link
US (1) US20180289655A1 (cg-RX-API-DMAC7.html)
EP (1) EP3270895A2 (cg-RX-API-DMAC7.html)
JP (1) JP2018508559A (cg-RX-API-DMAC7.html)
KR (1) KR20170138437A (cg-RX-API-DMAC7.html)
CN (1) CN107666905A (cg-RX-API-DMAC7.html)
AR (1) AR104029A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016235743A1 (cg-RX-API-DMAC7.html)
CA (1) CA2979544A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792076A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244680A1 (cg-RX-API-DMAC7.html)
IL (1) IL254576A0 (cg-RX-API-DMAC7.html)
MA (1) MA41785A (cg-RX-API-DMAC7.html)
MX (1) MX2017012239A (cg-RX-API-DMAC7.html)
TW (1) TW201642847A (cg-RX-API-DMAC7.html)
WO (1) WO2016153957A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DK1663197T3 (da) * 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
SI1799196T1 (sl) * 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2653873B8 (en) * 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP3318249A1 (en) 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
DK2533634T3 (en) 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
JP5072128B2 (ja) * 2011-03-31 2012-11-14 株式会社ワコール カップ部を有する衣類
US20140308244A1 (en) 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
EP2791181A4 (en) * 2011-12-16 2015-08-05 Biogen Ma Inc SILICONE-CONTAINING FUMIC ACID ESTERS
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2862885C (en) 2012-02-07 2020-06-02 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
US20140057918A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
EP3243511B1 (en) 2012-12-21 2019-03-20 ratiopharm GmbH Prodrugs of monomethylfumarate (mmf)
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
WO2016074684A1 (en) * 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use

Also Published As

Publication number Publication date
CN107666905A (zh) 2018-02-06
AR104029A1 (es) 2017-06-21
IL254576A0 (en) 2017-11-30
US20180289655A1 (en) 2018-10-11
EP3270895A2 (en) 2018-01-24
EA201792076A1 (ru) 2018-04-30
MX2017012239A (es) 2018-06-27
MA41785A (fr) 2018-01-23
JP2018508559A (ja) 2018-03-29
WO2016153957A3 (en) 2016-11-10
KR20170138437A (ko) 2017-12-15
TW201642847A (zh) 2016-12-16
WO2016153957A2 (en) 2016-09-29
HK1244680A1 (zh) 2018-08-17
AU2016235743A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
AU2020243692B2 (en) Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
NZ785712A (en) Neuroactive steroids, compositions, and uses thereof
JP7819094B2 (ja) ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法
JP5916746B2 (ja) 認知障害を処置するためのピリダジン誘導体、組成物、および方法
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP4032889A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3153305A1 (en) Methods for treating neurological disorders with ?1a-ar partial agonists
EP3651762A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2013542266A (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法
KR20220110251A (ko) 신경변성 질환과 연관된 인지 장애를 치료하는 방법
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
TW202345795A (zh) 純質形式之結晶型阿替卡普蘭
CN109862893A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
RU2686110C1 (ru) Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра
CN115175911A (zh) 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
JP2024525875A (ja) パーキンソン病及び／またはレビー小体型疾患または障害の処置方法
JP6808154B2 (ja) アダマンタン誘導体およびその使用
JPWO2019026994A1 (ja) アダマンチルメチルアミン誘導体およびその医薬としての使用
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
TW202027752A (zh) 使用ccr-3抑制劑治療老化相關損傷之方法及組合物
TW201035081A (en) Novel pharmaceutical composition for treatment of schizophrenia
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
JP2025519558A (ja) 抗うつ薬抵抗性対象の治療
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301